Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Myelodysplasia risk high in RCC patients

Shenoy N et al. Clinical Genitourinary Cancer, Published online June 28, 2018. https://doi.org/10.1016/j.clgc.2018.06.008

Key clinical point: Patients with a history of renal cell carcinoma have a substantially increased risk of developing myelodysplastic syndromes as compared to the general population. Given the strong association, an unexplained cytopenia in patients with a history of nephrectomy for localized RCC would warrant a strong consideration for a bone marrow biopsy to detect myelodysplasia.

Major finding: The prevalence of myelodysplastic syndromes in patients over 65 years old with a history of nephrectomy for RCC was 8.4 times that of the age-concordant general population based on the Dusseldorf registry (28/6490 or 395/100,000 vs. 47/100,000), and 3.07 times that of the age-concordant patient population at Mayo Clinic (28/6490 or 395/100,000 vs 128.4/100,000. Both differences were statistically significant (P less than 0.001).

Study details: Mayo Clinic’s ‘Advanced Cohort Explorer’ database was used to identify patients with a history of both malignancies. Prevalence of myelodysplastic syndromes was noted in patients aged 65 years and older with a history of nephrectomy for RCC and was compared to the prevalence of myelodysplastic syndromes in the Dusseldorf MDS registry and the general patient population at Mayo Clinic.

Disclosures: The authors had no relevant financial disclosures.

Source: Shenoy N et al. Clinical Genitourinary Cancer, Published online June 28, 2018. https://doi.org/10.1016/j.clgc.2018.06.008

Citation:

Shenoy N et al. Clinical Genitourinary Cancer, Published online June 28, 2018. https://doi.org/10.1016/j.clgc.2018.06.008

This Week's Must Reads

PFS superior with avelumab and axitinib in advanced RCC, Motzer RJ et al. ESMO 2018. Abstract LBA6_PR

Adjuvant axitinib may benefit highest risk RCC patients, Quinn DI et al. Ann Oncol. 2018 Oct 20. doi: 10.1093/annonc/mdy454

High KPNA2 signals poor outcomes for RCC, Kristiansen G et al. Clin Genitourin Cancer. 2018 Oct 22. doi: 10.1016/j.clgc.2018.10.008

RCC patient and disease characteristics differ by race/ethnicity, Batai K et al. Clin Genitourin Cancer. 2018 Oct 26. doi: 10.1016/j.clgc.2018.10.012

Change in tumor burden signals treatment needs in mRCC, Bimbatti D et al. Urol Oncol. 2018 Oct 6. doi: 10.1016/j.urolonc.2018.08.018

Must Reads in Renal Cell Carcinoma

PFS superior with avelumab and axitinib in advanced RCC, Motzer RJ et al. ESMO 2018. Abstract LBA6_PR

Adjuvant axitinib may benefit highest risk RCC patients, Quinn DI et al. Ann Oncol. 2018 Oct 20. doi: 10.1093/annonc/mdy454

High KPNA2 signals poor outcomes for RCC, Kristiansen G et al. Clin Genitourin Cancer. 2018 Oct 22. doi: 10.1016/j.clgc.2018.10.008

RCC patient and disease characteristics differ by race/ethnicity, Batai K et al. Clin Genitourin Cancer. 2018 Oct 26. doi: 10.1016/j.clgc.2018.10.012

Change in tumor burden signals treatment needs in mRCC, Bimbatti D et al. Urol Oncol. 2018 Oct 6. doi: 10.1016/j.urolonc.2018.08.018